Malaria Chemoprophylaxis of 3,446 French Travelers Departing from Paris to Eight Tropical Countries

Abstract

This study shows that the quality of advice on antimalarial chemoprophylaxis varies markedly according to the source, and that nearly one in three French travelers (29.3 %, 850/2899) to tropical areas is at risk of malaria.

Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa: Cost-effectiveness analysis from the perspective of the French national health insurance system

“…In contrast, most French residents travelling to East Africa are not VFR but tourists of European origin. This difference may explain that, among French residents travelling to SSA, recourse to MC is much higher among travellers who visit East Africa [24] than among those who visit West and Central Africa [13,17,18].…”

“…A 2-week average length of stay (ALS) was considered, in agreement with previously published data [13,[17][18][19][20][21]31,53].…”

“…We considered the average probability of recourse to MC among the whole travellers from France, whatever their origin. The recourse to MC was estimated at 55% among travellers to West and Central Africa [13,17,18] and at 95% among travellers to East Africa [24]. Finally, the average probability of recourse to a MC used in our analysis was estimated at 63% (equivalent to a foregone MC at 37%) balancing the proportion of journeys (n; %) of travellers from France to West Africa (Table 3).…”

“…This estimate was based on published data concerning travellers to SSA, whether they travelled from France [13,17,18] or from other European countries [19][20][21][22][23][24]. The recourse to MC among VFR was estimated at 46% according to Hamer and Connor [25] and at 57% according to Pistone et al [13] (57% adjusted at 42-52% by a method available on request).…”

“…The recourse to MC among VFR was estimated at 46% according to Hamer and Connor [25] and at 57% according to Pistone et al [13] (57% adjusted at 42-52% by a method available on request). In the same manner, the recourse to MC among travellers of European origin was estimated respectively at 53%, 54%, 57%, 58%, 60%, 63% and 95% according to Gisler et al [23], Malvy et al [17], Semaille et al [18], Laver et al [19], Toovey et al Decision tree modelled to estimate costs a and effectiveness b of 65% reimbursement (MC 65%) * of malaria chemoprophylaxis recommended in France (MC) for French residents travelling to Sub-Saharan Africa; from the perspective of the French national health insurance system (FHS). * Compared to the current situation in France without reimbursement rule (MC 0%).…”